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Keith Zachary Sabin 
 
 Glioblastoma multiforme is the most common and malignant brain tumor in 
adults. Despite an intensive treatment regimen the average survival after diagnosis 
remains only 15 months. Novel therapies are desperately needed. While recent successes 
with immune based therapies, in targeting brain tumors, are promising widespread 
clinical efficacy has yet to be demonstrated. Glioblastoma patients are systemically 
immune suppressed and to increase the effectiveness of immune based therapies these 
immunosuppressive pathways must be neutralized. A possible role for glioblastoma-
derived exosomes in immune suppression has never been investigated. Exosomes are 
small membrane-bound vesicles of endocytic origins that contain mRNA and proteins 
and are secreted by a variety of cell types, including brain tumors. We have shown that 
glioblastoma-derived exosomes are capable of decreasing T cell viability. In order to 
delineate the signaling pathway responsible for reduced T cell viability a Fas neutralizing 
antibody was utilized which yielded enigmatic results. However, glioblastoma-derived 
exosomes activated a caspase cascade indicative of Fas signaling and the activation of the 
extrinsic apoptotic pathway. This is a novel form of immune suppression in glioblastoma 
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Chapter 1: Literature Review 
 
Glioblastoma multiforme: Prognosis, Treatment and Immune Suppression 
 Glioblastoma multiforme (GBM), also known as a grade IV astrocytoma, is the 
most common and malignant primary brain tumor in adults. Hallmarks of GBM include 
its heightened proliferative potential and extensive neovascularization. The ability of 
GBM to proliferate so rapidly is due, in part, to the inactivation of the major tumor 
suppressor genes retinoblastoma protein (pRb)
1
 and phosphatase and tensin homologue 
(PTEN)
2
. The inactivation of these tumor suppressors allows for an uninhibited 
progression through cell cycle checkpoints. GBM is highly vascularized due to increased 
expression of the pro-angiogenic molecules stromal derived factor-1 (SDF-1), fibroblast 
growth factor (FGF), interleukin-8 (IL-8) and vascular endothelial growth factor 
(VEGF)
3
. Neovascularization of the tumor is such a defining characteristic of GBM that 
it prompted investigations into whether or not blood vessel density could be used as a 
prognostic indicator. As it turns out, the extent of vascularization proved to be inversely 
correlated with mean survival in patients with astroglial tumors
4,5
.  
 The current gold standard of treatment for GBM patients includes maximal 
surgical resection coupled with radiation and chemotherapy. The current chemotherapy 
most widely administered to patients with newly diagnosed GBM is the alkylating agent 
temozolomide (TMZ)
6
. TMZ acts by adding a methyl group to the O
6
 position on the 
nucleotide, guanine. This methyl adduct inhibits the ability of the cancer cell to correctly 
replicate its DNA. Base excision repair pathways are activated to replace the 
methylguanine with a guanine. However, TMZ methylates the O
6
 position of the new 
nucleotide leading to activation of base excision repair pathways yet again. This leads to 
2 
 
single stranded DNA breaks and futile mismatch repair cycles inevitably leading to cell 
death (Figure 1)
7
. A major mechanism of TMZ resistance in GBM is mediated by the 
expression of the enzyme O
6
-methylguanine-methyltransferase (MGMT). MGMT 
specifically recognizes O
6 
methyl adducts on guanine and removes them
7
. MGMT 
effectively neutralizes the cytotoxic abilities of TMZ. It was shown that patients with a 
methylated MGMT promoter, which effectively silences gene expression, respond better 
to TMZ treatment than patients with an unmethylated MGMT promoter
8
. However, 
despite this aggressive multi-modality treatment regimen the average survival rate after 
diagnosis is only 15 months with a 5 year survival rate of less than 4%
6,9
. Novel 
treatments are desperately needed and recently increased efforts have gone into the 













Figure 1: Mechanism of MGMT mediated Chemoresistance. TMZ generates a spectrum of DNA 
lesions including O6-methylguanine, N3-methyladenine and N7-methylguanine. MGMT directly 
eliminates the methyl group from O6-methylguanine, whereas base excision repair pathway includes 
multistep reaction by DNA glycosylase (APNGorMPG), endonuclease, polymeraswe and DNA ligase. 
DNA glycosylase recognizes and removes the damaged bases. The abasic site is then hydrolyzed by 
endonuclease, resulting in the incision of the damaged DNA strand. Polymerase inserts a single nucleotide 
and DNA ligase completes the repair process. Poly (ADP) ribose polymerase, one of the polymerases of 
the base excision repair pathway, catalyzes the transfer of ADP-ribose units from NAD+ to target proteins 
including PARP itself. Therefore, inhibition or hyperactivation of PARP leads to accumulation of broken 
DNA or NAD+ depletion respectively, consequently inducing cell death. 
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 The immune system in patients that develop tumors has already failed. The 
immune system is capable of recognizing a cancerous cell and destroying it. However, in 
cancer patients, the immune system is sufficiently suppressed to the point that it is unable 
to mount a robust antitumor response without clinical intervention. Components of the 
immune system are being used in clinical settings to help manage different disease states, 
and these fall into two broad categories: passsive immunotherapy and active 
immunotherapy.  
 Passive immunotherapies include the use of antibodies, cytokines and antigen 
unrestricted lymphocytes
10
. One monoclonal antibody whose clinical relevance is being 
investigated in GBM  is bevacizumab
11–13
. Bevacizumab is a monoclonal antibody 
recognizes the pro-angiogenic molecule VEGF, which, as discussed earlier, plays an 
important role in glioma progression. The antibody binds to VEGF in such a way that it 
inhibits its ability to bind its cognate receptor, thereby antagonizing the formation of new 
blood vessels
13
. Clinicians have also investigated using injections of potent immune 
stimulatory cytokines, such as interleukin(IL)-2. This approach, in theory, is thought to 
help lymphocytes overcome tumor-derived, immunosuppressive factors and stimulate 
them to proliferate and subsequently differentiate into effector and memory cells. IL-2 
therapy has been successful in melanoma and renal cell carcinoma
14
 but its clinical 
efficacy has not been demonstrated in the case of GMB
15
. Another method involving 
passive immunotherapy that has been utilized in the treatment of GBM includes the ex 
vivo activation of tumor infiltrating lymphocytes (TILs) and subsequent infusion of the 
activated lymphocytes back into the patient
16–18
. It is proposed that lymphocytes found 
within the tumor are more likely to be reactive to tumor antigens. The lymphocytes are 
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activated ex vivo then reintroduced into the patient and should be able to mount a robust 
antitumor immune response. 
 Active immunotherapies involve the in vivo stimulation of a patient’s immune 
system to mount an antigen-specific antitumor attack. The most common forms of active 
immunotherapies utilize peptide-based vaccines or employ the antigen presenting 
capabilities of dendritic cells
10
. Both treatment modalities have been and continue to be 
investigated in the treatment of GBM. One of the biggest obstacles of advancing active 
immunotherapies is finding an antigen that is tumor specific and not expressed by healthy 
cells. A very attractive tumor specific antigen found in GBM is epidermal growth factor 
receptor variant III (EGFRvIII). EGFRvIII is a constitutively active, truncated receptor 
that lacks the extracellular ligand binding domain. It is a common antigen in GBM that is 
not expressed elsewhere in the body. The mutation responsible for its constitutive 
activation causes a novel sequence of amino acids to be exposed on the extracellular 
surface of the cell. This epitope has been mapped and developed into a peptide based 
vaccine
19–22
. The injection of this specific peptide into patient with EGFRvIII positive 
tumors is sufficient to evoke a robust and antigen specific antitumor immune response in 
a cohort of patients
21,22
.  
 Another commonly used form of active immunotherapy involves the isolation of 
patient monocytes which are then differentiated into dendritic cells ex vivo. These 
patient-derived dendritic cells can be pulsed with autologous tumor lysate and 
reintroduced into the patient. Once in the patient, the dendritic cells appropriately process 
the tumor antigens and display them to the immune system and initiate an antitumor 
immune response
23–26
. While success with immune-based therapies has been reported in 
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GBM studies, they are rare, with only modest improvements to current survival rates. 
These results differ from reports from other types of cancer including melanoma and 
renal cell carcinoma which respond well to certain types of immunotherapies
14,15
. This 
leads to the question: What is it about the nature of GBM that makes it refractory to 
immune based therapies? 
 One potential answer to this question is simply the location of the tumor. Gliomas 
arise in the brain and rarely ever metastasize from the central nervous system (CNS). The 
brain has long been considered an immune privileged organ that is ill suited to initiate or 
maintain an immune response. Therefore, addition of immune cells to the tumor cavity or 
to the periphery should have little influence on tumor cells residing within this immune 
privileged niche. However, recent evidence suggests that the brain is far from the 
immune-isolated organ that it was once thought to be, and as such, provides an 
environment conducive to the formation and persistence of an antitumor immune 
response. An alternative answer, that is likely underappreciated, is the degree of immune 
suppression afforded by the tumor both locally, in the tumor microenvironment, and 
systemically. Both the immune status of the CNS and immunosuppressive mechanisms 
employed by GBM will be discussed presently. 
 For decades, the brain was considered an immune privileged organ for several 
reasons: (1) there was no apparent draining lymph node from the CNS, (2) it was thought 
the blood brain barrier (BBB) provided an absolute barrier to circulating peripheral 
leukocytes and (3) the relatively low numbers of antigen presenting cells (APCs) within 
the CNS was not conducive to the stimulation of an immune response. These notions 
have recently been disavowed. 
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 Several studies have shown that cerebrospinal fluid (CSF) can drain through the 
Virchow-Robbin spaces to the deep cervical lymphatics
27–29
. One of the first indicators 
that antigens from the CNS could stimulate an immune response was provided by 
microinjection of human serum albumin (HSA) into the CSF of rats
29
. The injection of 
HSA into the CSF of rats was sufficient to elicit anti-HSA antibody production with the 
increased antibody titer persisting over 10 weeks
29
. Obstruction of the cervical lymph 
nodes was able to inhibit the formation of HSA reactive antibodies
29
. Further support that 
CNS antigens are capable of entering the lymphatics was provided by studies utilizing 
radiolabeled albumin. The labeled proteins were microinjected into the CSF or brain of 
rabbits, cats and sheep, and they were able to trace the radiolabeled protein as they 
migrated from the CNS into lymph
28
. These studies provide compelling evidence that 
soluble antigens from the CNS are capable of entering into the lymphatics and are able to 
stimulate humoral and cellular immune responses. 
 Additional studies sought to characterize the ability of T lymphocytes to cross the 
BBB and enter into the CNS. Naïve T cells were unable to enter into the CNS but 
activated T cells are capable of extravasation across the BBB and gaining entrance to the 
CNS
30,31
. Activated T cells are capable of crossing the BBB via interactions between cell 
adhesion molecules found specifically on activated T cells and on the brain vasculature
31
. 
Specifically, it appeared that alpha 4 integrins were essential to T cell trafficking into the 
CNS. These studies also demonstrated that activated T cells are capable of entering the 
CNS, independent of antigen specificity, and can then reenter circulation to patrol other 
organs. These data indicate the ability of T cells to enter the CNS is dependent on their 





 Another reason the CNS was thought to be an inhospitable environment for the 
formation of an immune response was the relative lack of professional APCs. APCs are a 
specialized type of immune cells that are responsible for stimulating antigen specific 
immune responses. It is now clear that CNS accessory cells called microglia, which arise 
from bone marrow-derived cells, are fully competent to act as resident macrophages in 
the CNS
32
. Functionally and phenotypically, microglia are capable of processing and 
presenting antigens in a manner similar to the dendritic cells of the periphery
32–34
. They 
express class II major histocompatibility complex and the appropriate co-stimulatory 
molecules necessary for antigen presentation and activation of T lymphocytes
35
. In 
experiments using primary microglia cultures, it was shown that these cells were 
sufficient for activation of T cells both in vitro and in vivo
34,36
.  
 Taken together, these lines of evidence dispel the notion of the brain as an 
“immune privileged” organ. Antigens from the CNS are capable of entering into the 
lymphatics system and eliciting a measurable and sustained humoral and cellular 
response
27–29
. Studies demonstrate that activated T cells are capable of crossing the BBB, 
and participate in an immune response
30,31
. CNS accessory cells in the form of microglia 
function as APCs that express the necessary MHC molecules and co-stimulatory factors 
necessary for the formation of a successful immune response
32–36
.  
 However, while the CNS has all the hallmarks of an immune competent organ it 
is important to note that, while the BBB does not form an absolute barrier to leukocytes it 
does seem to prevent the excursion of naïve T lymphocytes into the brain parenchyma
31
. 
Taking this into account, it is probably more accurate to refer to the CNS as an “immune-
restricted” organ. Passive incursions by circulating naïve lymphocytes into the brain 
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parenchyma seem to be restricted, presumably by the presence of the BBB, but activated 
lymphocytes are fully capable of circumventing the BBB. What, then, is the nature of 
GBM-derived immune suppression? 
 It’s been more than 40 years since the first observations indicating that cellular 
immunity in glioma patients was suppressed
37,38
. This state of immune suppression is 
absent in patients prior to tumor formation. Studies investigating the functionality of 
cellular immune responses in patients pre- and post-tumor resection indicated that these 
deficiencies are reversed after tumor resection but return upon recurrence
39
. The 




 Lymphocytes isolated from peripheral circulation of GBM patients exhibit 
extensive abnormalities in their ability to undergo clonal expansion in vitro in response to 
mitogen stimulation
42
. It was shown that the inability of T cells isolated from GBM 
patients to undergo proliferation was due to defects in the IL-2/IL-2 receptor (IL-2R) 
pathway
43,44
. The IL-2 receptor is comprised of three polypeptides, designated the α- β- 
and γ- chain
45
. Naïve T cells express an intermediate affinity IL-2R comprised of a β-
chain and a γ-chain. The expression of the high affinity IL-2R is necessary for clonal 
expansion and subsequent T cell activation
46–48
. Following antigenic stimulation, T cells 
begin to express the α-chain, which is required for the formation of the high affinity IL-
2R
45,46,49
. T cells obtained from GBM patients did not express the high affinity IL-2R
50
 
and this deficiency was later demonstrated to be in response to a tumor-derived 
immunosuppressive factor
51
. Further supportive evidence for the existence of a soluble 
tumor-derived immunosuppressive factor capable of mediating these effects was 
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provided by experiments that cultured primary T cells from healthy individuals in 
glioma-conditioned medium. In response to activating stimuli these T cells exhibited 
similar deficiencies in IL-2 secretion and lacked expression of the high affinity IL-2R, 
CD25, indicating a role for a tumor specific soluble immunosuppressive factor in T cell 
inhibition
52–54
.   
 Further studies aimed at characterizing the soluble immunosuppressive factor 
responsible for these T cell deficiencies identified transforming growth factor (TGF)-
β2
55,56
. Eventually expression of all three isoforms of TGF-β was demonstrated for 
GBM
57,58
. The potent immune suppressive role of TGF-β was demonstrated for 
melanoma using mice genetically engineered to have T cells express a dominant 
negative, or inactive, form of the TGF-β receptor
59
. Mice whose T cells expressed the 
nonfunctional dnTGF-β receptor were able to reject the tumor, while wild type mice, who 
expressed a functional TGF-β receptor, were unable to reject the tumor and succumbed to 
tumor burden
59
. The physiologic consequences of TGF-β expression by GBM takes on 
additional significance in light of recent findings that TGF-β is capable of inducing 




 Regulatory T cells (Tregs) are a subset of T cells phenotypically defined by the 
expression of CD4, CD25 and the foxhead transcription factor, FoxP3
62
. Tregs  are 
capable of inhibiting effector T cell function in a variety of ways including: (1) TGF-β 
induced immune suppression, (2) release of the immunosuppressive cytokine IL-10 and 
(3) ability to release the immunosuppressive factor adenosine
62–64
. Recently, an increased 





. Another immunosuppressive mechanism employed by GBM is the 
expression of the pro-apoptotic molecule Fas ligand (FasL). 
 FasL is capable of binding to its receptor, Fas, and activating the intrinsic 
apoptotic pathway which results in completion of programmed cell death. This pathway 
will be discussed in more detail later. The Fas/FasL system is thought to be an important 
pathway involved with the homeostatic regulation of immune responses. Activated T 
cells constitutively express Fas which is thought to be a key mediator of activation 
induced cell death (AICD). AICD functions as the brakes to an immune response and 
helps to ensure that an inappropriate immune response does not occur. The physiologic 
importance of this pathway becomes evident in individuals who have autoimmune 
lymphoproliferative disease (ALPS). While there are several different classifications of 
ALPS, they all result from different mutations to the FAS gene. These mutations are all 
loss of function and results in lymphocyte resistance to FasL-induced apoptosis
67
. This 
resistance to FasL-mediated apoptosis in those T cells allows for massive proliferation of 
lymphocytes and the development of inappropriate immune response. While FasL-
induced apoptosis is a physiologic function, this mechanism is exploited by a number of 
tumor types including GBM as a potent immune suppressive mechanism
68
. The 
overexpression of FasL is a necessary event early in the carcinogenesis of colon cancer
69
.  
The functional significance of FasL expression has been demonstrated for GBM in vitro 
and in vivo.  
 FasL expression was confirmed in freshly resected tumors and established cell 
lines using Western blotting
68
. When GBM cells were co-cultured with T cells, it was 
sufficient to stimulate apoptosis in the T cells. The necessity of FasL to induce apoptosis 
11 
 
was demonstrated by the ability of a FasL neutralizing antibody to rescue T cells from 
apoptosis in the co-culture assay
68
. When GBM cells, engineered to no longer express 
FasL, were injected into immune competent rats, the resulting tumor grew significantly 
slower and had an increased presence of tumor infiltrating lymphocytes, as compared to 
tumors generated from wild type GBM cells
68
. 
 It is apparent that patients with GBM exhibit severe immune suppression, both in 
the tumor microenvironment and in the periphery. This immune suppression is mediated 
by a number of membrane bound factors, such as the pro-apoptotic molecule FasL, and 
soluble secreted factors, like TGF-β
57,68
. It is clear that in order for future immune-based 
therapies to mount a robust and reproducible anti-tumor effect, the immune suppressive 
pathways employed by the tumor need to be better understood. While the above-
mentioned pathways are under intensive experimental investigation, the role tumor-
derived exosomes play in immune suppression remains largely uncharacterized.  
Exosomes: Biogenesis and Function 
 In order to communicate, cells secrete factors into the extracellular environment. 
These factors are a diverse group of signaling components, ranging from macromolecular 
complexes, to soluble proteins, to modified fatty acid chains. These secreted factors are 
capable of influencing the behavior of neighboring cells in response to a specific or a 
series of stimuli. One mode of cell-to-cell communication that is receiving increased 
attention is one which is mediated by exosomes. Exosomes are small (50-100 nm) 
membrane-bound vesicles of endocytic origin that are released by a diverse array of cell 
types, including cancer cells. Exosomes contain membrane and soluble proteins, as well 
12 
 
as m RNA and miRNA
70,71

















 Exosomes were first described as “exfoliated vesicles” that possessed ectoenzyme 
activity and were capable of acting as a 5’ exonucleotidase
73
. Studies performed several 
years later were able to show that sheep reticulocytes shed transferrin receptors as they 
differentiated in similar structures
74,75
. Since these reports, much has been learned about 
the origin of these structures. Exosomes correspond to the intraluminal vesicles (ILV) 
present in multivesicular bodies (MVBs)
76–78
. ILV arise from the invagination of the 
limiting membrane of early endosomes and the accumulation of ILV leads to the 
formation of MVB. At this point, MVBs enter one of two pathways. They either fuse 
Figure 2: An overview of the Exosomal Pathway. Exosomes correspond to the intraluminal vesicles (ILV) 
found in multivesicular bodies (MVB). Mature MVB can either enter the lysosomal pathway resulting in the 
degradation of its contents or it can fuse with the plasma membrane thus releasing the ILV as exosomes into 
the extracellular environment. Exosomes contain membrane proteins, soluble proteins, mRNA and miRNA. 
Once in the extracellular environment exosomes can either directly fuse with the membranes of recipient 
cells or can be internalized through endocytosis. The physiology of the recipient cell will be appropriately 
influenced by the molecular composition of the exosome. 
13 
 
with lysosomes and its contents are degraded, or they fuse with the plasma membrane 
and release the ILV as exosomes
79
.  
 Formation of ILV is not well understood, but increasing evidence suggests that 
clustering of proteins in the limiting membrane of the early endosome promotes 
membrane invagination and ILV creation. Experimental evidence utilizing crosslinking 
antibodies or aceylated reporter proteins support this notion. Inducing the aggregation of 
the transferrin receptor in maturing rat reticulocytes or of major histocompatibility 
complex class II  (MHC class II) complexes in activated B cells via crosslinking 
antibodies increased their localization to the endosomal compartment and subsequent 
secretion in exosomes
80,81
. Consistent with these results, the presence of multiple 
oligomerization domains in an acylated reporter protein increased the presence of the 
reporter protein in exosomes
82
. Taken together these data demonstrate a role for cargo 
clustering in ILV formation. 
 Another mechanism that seems to play a role in the formation of ILV involves the 
endosomal sorting complex required for transport (ESCRT) proteins. There are four 
predominant members of the ESCRT complex: ESCRT-0, -I, -II, -III
83
. The function of 
ESCRT-0, -I and -II involve interacting with and retaining ubiquitinated proteins in the 
endosomal compartment, while ESRCT-III plays a role in membrane budding
84,85
. The 
interactions of ESCRT-0, -I and -II with ubiquitinated proteins could indirectly stimulate 
ILV formation by promoting the clustering of ubiquitinated proteins in the limiting 
endosomal membrane. Previous studies indicated that protein clustering promoted their 
release in exosomes
80–82
. The action of ESCRT-III could directly promote ILV formation 
through the stimulation of membrane budding of the early endosomal membrane. While 
14 
 
evidence suggests a role of ESCRT-dependent ILV formation, it appears that ILV can 
form in an ESCRT-independent mechanism. 
 Recent experimental evidence suggests that the accumulation of the 
sphingomyelin, ceramide, plays a role in ILV formation and the promotion of exosome 
secretion. Studies focusing on the biochemical composition of exosome-associated lipids 
found that cholesterol, ceramide and its derivative hexosylceramide, were enriched in the 
membranes of exosomes when compared to the parent cell
86
. The enzyme neural 
sphingomyelinase (nSMase) is responsible for the production of ceramide. When nSMase 
function was inhibited either through pharmacological means or small interfering RNA 
(siRNA) applications, ceramide was drastically reduced in the parent cells and the 
amount of exosomes being released was significantly decreased
86,87
. Furthermore, 
transfecting cells with a vector encoding nSMase, thereby increasing the expression 
levels of this enzyme, caused an increase in exosome secretion
87
. This increase in 
exosomes secretion was independent of ESCRT expression
87
. Further investigation will 
be required to determine the pathways necessary for ILV formation and the regulation of 
MVB fate. 
 Another category of membranous vesicles released by cells is referred to as 
microvesicles (MV). MV (100-1,000nm) are larger than exosomes (50-100nm) and are 
the result of an independent biosynthetic pathway. They arise from the direct budding of 
the plasma membrane
88
 via a mechanism dependent on increased calcium permeability
89–
91
 and the activation of calpain
92
. More extensive characterization of the contents of MV 
indicate that they are enriched with lipid raft-associated molecules and cholesterol
90,91
. 
While the biosynthetic pathways and molecular composition of Mvs may differ from 
15 
 
exosomes, the ability of these different populations of membranous vesicles to diffuse 
away from the cell of origin and influence the physiology of recipient cells is becoming 
increasingly appreciated
93,94
. Studies utilizing exosomes isolated from cancer cells have 
greatly contributed to the understanding the role exosomes could play in cancer 
progression. 
 Tumor-derived exosomes potentially contribute to tumor progression by 
modulating a variety of pathways including immune suppression, cell proliferation, 
angiogenesis and metastasis
95–98
. As previously mentioned, a common oncogenic 
receptor expressed by GBM cells is the truncated, constitutively active EGFRvIII. 
Exosomes isolated from established GBM cells lines that express EGFRvIII contain 
functional receptor and are able to transfer the receptor to cells that do not normally 
express EGFRvIII
95,96
. Exosomal-mediated transfer of the receptor led to a significant 
increase in proliferation, of the recipient cells. This response was specific to the transfer 
of EGFRvIII as exosomes isolated from GBM cells lines that did not express the 
oncogenic receptor were unable to significantly increase proliferation
95,96
. In addition to 
increased proliferation the exosomal mediated transfer of EGFRvIII was shown to 
increase the secretion of the pro-angiogenic protein VEGF, induced activation of the Akt 
and MAPK/Erk pathway, upregulated the expression of the anti-apoptotic protein Bcl-xL 
and down regulated the expression of p21
cip1
, an inhibitor of cell cycle progression
27
.  
 A second study using GBM-derived exosomes corroborated the ability of 
EGFRvIII containing exosomes to transfer a functional receptor and increase the 
proliferation of recipient cells
96
. In addition, the composition and functional implications 
of mRNA extracted from GBM-derived exosomes was also investigated. Using 
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microarray technology it was determined that approximately 4,700 transcripts were 
specifically enriched in the exosome fraction and absent from the parent cells
96
. The 
functions of these mRNA were investigated using bioinformatic analysis, and the most 
common function of the enriched mRNA was involved in cell proliferation pathways, 
immune response, angiogenesis and migration
96
. Interestingly, the mRNA composition in 
exosomes isolated from two different tumor samples poorly correlated with the mRNA 
composition of the respective parent cells, while the mRNA composition of the exosome 
samples or the parent cells was strongly correlated
96
. These data suggest a conserved 
mechanism for the specific enrichment of certain mRNAs into GBM-derived exosomes. 
This is particularly interesting when considering that the specifically enriched mRNA 
contribute to pro-tumor pathways such as proliferation and angiogenesis. 
 Further evidence suggesting tumor-derive exosomes contribute to angiogenesis 
comes from a study evaluating the composition of mRNA from colorectal cancer cell-
derived exosomes
98
. Using microarray technology 241 mRNAs were found to be 
enriched above levels determined for the parent cells. Of those 241 transcripts, 27 were 
found to be involved with cell cycle progression, specifically for M-phase progression
98
. 
When colorectal cancer-derived exosomes were incubated with endothelial cells, this was 
sufficient to increase the proportion of cells undergoing mitosis
98
 thus providing evidence 
that exosomes contribute to angiogenesis by promoting the division of endothelial cells. 
 A role for tumor-derived exosomes has also been implicated in immune 
suppression. Exosomes isolated from a diverse set of tumor types including melanoma, 
colorectal cancer and prostate cancer are capable of inducing T cell apoptosis via a Fas 
ligand (FasL) dependent mechanism
99–101
. FasL stimulates programmed cell death, or 
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apoptosis, by binding to its receptor, Fas, and initiating a caspase cascade in the Fas-
expressing cell. FasL is often over expressed in tumor cells, including GBM
102,103
. 
Exosomes isolated from cultured cancer cell lines and incubated with either established T 
cell lines
99,100
, activated, or resting primary peripheral blood mononuclear cells 
(PBMCs)
100
 or primary CD8+ cytotoxic T cells
100,101
 were capable of inducing apoptosis 
in all cells tested. However, the ability of tumor-derived exosomes to induce apoptosis 
was restricted to cells that expressed Fas. Furthermore, addition of a Fas neutralizing
99,100
 
or a FasL neutralizing
101
 antibody was sufficient to inhibit the ability of tumor-derived 
exosomes to induce apoptosis. It has been shown that GBM cells express FasL
102
 
however the presence of FasL in GBM-derived exosomes has not been reported. 
Apoptosis: Fas ligand/Fas/DISC/Caspase-8 
 Programmed cell death, or apoptosis, is a tightly regulated physiologic function. 
In 1842, Carl Vogt was the first to propose the idea that cells are capable of undergoing 
natural cell death. The first documentation of the morphological changes associated with 
this natural cell death program was provided by Walther Flemming in 1885 and in 1972 
the term apoptosis was first proposed
104,105
. As our understanding of apoptosis grew, 
cancer researchers desperately searched for ways to exploit this pathway for the 
successful treatment of cancer. Several researchers sought to develop monoclonal 
antibodies that were capable of activating the apoptotic program in both malignant and 
normal cells
106,107
. It was later determined that two of the most potent monoclonal 
antibodies developed, anti-APO-1 and anti-Fas, were capable of recognizing similar 
epitopes and activating the same cell surface antigen. Subsequent cloning experiments 
determined that the antigen recognized by the antibodies belonged to the Tumor Necrosis 
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Factor Receptor superfamily (TNFRSF); specifically the pro-apoptotic cell surface 
receptor, Fas
108
. Other members of the TNFRSF include TNF receptor, CD40 and TNF-
related apoptosis inducing-ligand receptor (TRAIL-R)
109
.  
 TNF receptors are type I transmembrane receptors, meaning the N-terminus is 
oriented on the extracellular surface, and there is one transmembrane domain and the C-
terminus is oriented on the intracellular surface
108,110
. A defining hallmark of TNFRs is 
the presence of several cysteine-rich domains (CRD) in their extracellular domain. 
Depending on the receptor, there can be up to six CRDs.  The CRDs are capable of 
forming intrapeptide disulfide bonds which are indispensable for receptor stability and 
function
110




 While the TNFRSF encompasses many different receptors that are involved in a 
variety of cellular processes, there is a subgroup of TNFRSF members referred to as the 
death receptors (DR). Eight members of the DR subgroup have been characterized: 
TNFR1, Fas, DR3, TRAILR1, TRAILR2, DR6, ectodysplasin A receptor (EDAR), and 
nerve growth factor receptor (NGFR)
112
. These receptors were initially characterized by 
their ability to induce programmed cell death in response to ligand binding and receptor 
activation. While the biochemical structure of the receptors varies, one unifying feature 
of the DRs is the presence of a highly conserved sequence consisting of 80 amino acids 
located in the cytoplasmic tail
113
. This conserved sequence is referred to as the death 
domain (DD) and mediates homotypic interactions with other DD containing proteins. A 
functional DD is essential for the recruitment of the appropriate protein complexes to 
initiate apoptosis. While there are several members of the DR subgroup, Fas is 
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considered the prototypic DR and therefore it’s structure and signaling cascade have been 
and continue to be the focus of intensive research efforts
109,114–116
.  
 Since Fas was cloned in 1991, extensive studies have aimed at investigating the 
FAS gene organization and protein structure. The FAS gene is located on chromosome 
10q24.1, includes 9 exons and spans 26kb of DNA
117
. The mature Fas transcript codes 
for a type I transmembrane receptor of 319 amino acids. The extracellular domain 
consists of amino acids 1-157 and contains three CRDs. The intracellular domain consists 















 The ligand responsible for activating Fas belongs to the Tumor Necrosis Factor 
family of ligands and is called Fas ligand (FasL). The FASL gene is located on 
chromosome 1q23, spans approximately 8kb of DNA and contains four exons
118
. Similar 
Figure 3: A Schematic Diagram of Fas and FasL Structure. The structure of Fas and FasL and 
the location of relevant domains. The numbers indicate amino acid positions. TM = transmembrane, 
PRD = proline rich domain, CRD = cysteine rich domain, THD = TNF homology domain. 
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to a majority of TNF ligands the FASL gene encodes a type II transmembrane 
glycoprotein
119
. The extracellular C-terminus of FasL contains three potential N-
glycosylation sites
119,120
 and is assembled in a “jelly roll” structure comprised of two 
antiparallel β-sheets
120,121
. The “jelly roll” structure is a common motif found in TNF 
family ligands and is therefore known as TNF homology domain (THD); (Figure 3)
115,121
. 
Interestingly, studies looking at the amino acid sequences of different TNF ligands have 
shown that sequence homology at the THD is no greater than 35%. It turns out, the 
conserved tertiary structure of the THD mediates ligand homotrimerization and receptor 
binding
122
.   
 Direct protein-protein interactions between FasL and Fas were mapped to CRD2 
and CRD3 found in the extracellular region of Fas. No direct ligand/receptor interactions 
were found for CRD1
123,124
. However, while there are no direct interactions between 
FasL and CRD1 the structural integrity of CRD1 is important for receptor signaling. 
When CRD1 is mutated or absent, it is sufficient to severely inhibit the ability of Fas to 
induce apoptosis in response to ligand binding
124
.  It would appear that while CRD1 does 
not participate in ligand binding, it is indispensable for receptor activation and 
subsequent signaling.  
 A possible explanation for these disparate results came with the discovery that in 
order to be fully functional several members of the TNFRSF (TNF receptor, CD40 and 
TRAIL-R1) need to pre-assemble into homotrimeric complexes. The formation of 
receptor complexes is independent of ligand binding and if the homotypic interactions 
mediating subunit trimerization were interrupted the receptors were nonfunctional
125
. The 
corresponding domain was named the pre-ligand association domain (PLAD). While this 
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study looked at several members of the TNFRSF it did not directly investigate Fas 
signaling. However, given the previous experimental data correlating CRD1 integrity and 
the ability of Fas to activate apoptosos
123,124
 it seems plausible that Fas could behave in a 
similar manner.  
 In order to investigate if Fas signaling was regulated by a similar mechanism, 
experiments utilizing yeast two-hybrid and Forrester’s resonance energy transfer 
experiments were performed
67,126
. As it turns out, when CRD1 was mutated or deleted 
Fas subunits were unable to oligimerize. The inability of Fas subunits to interact with 
each other directly inhibited its ability to induce apoptosis
67,126
. Recent studies have 
precisely mapped the region of Fas necessary for subunit association and found the 
minimal amino acid sequence required for subunit trimerization resides between amino 
acids 43-66
127
, which overlaps with CRD1 (amino acids 47-84)
115
. Taken together, these 
lines of evidence indicate that upon mutation of PLAD, Fas subunits are unable to form 
homotrimeric complexes. The inability of Fas to pre-assembly directly abrogates its 
ability to induce apoptosis. 
 While early studies using agonistic antibodies were capable of showing that Fas 
signaling leads to apoptosis
106,107
, the biochemical pathway that Fas activated remained 
elusive. Initial studies targeting Fas used co-immunoprecipitation to show that in 
response to receptor activation a high molecular weight, multi-protein complex was 
associated with Fas
128
. When Fas constructs that lacked or had a nonfunctional DD were 
expressed in primary and established cell lines, the formation of this multi-protein 
complex was not observed. Expression of these mutant Fas constructs rendered the cell 
lines insensitive to Fas-induced apoptosis
128
. These findings were consistent with 
22 
 
previous experiments that demonstrated that the DD was necessary for Fas-induced 
apoptosis
129
. Taken together, these data indicated that a functional DD is required for the 
formation of a multi-protein complex which is directly responsible for the transduction of 
the apoptotic signal. As a result, this multi-protein complex was named the death 
inducing signaling complex or DISC
128
. While there are many proteins capable of 
forming the DISC the four most abundant proteins are Fas Associated Death Domain 
(FADD), procaspase-8 (also known as FLICE), procaspase-10 and FLICE-like Inhibitory 
Protein (c-FLIP) (Figure 4)
109,130–134
. The protein c-FLIP has anti-apoptotic functions and 











 The events immediately following Fas activation that allows for the formation of 
the DISC remain unclear but recent evidence provided by X-ray crystallography has 
begun to shed light on the issue. In response to ligand binding, Fas undergoes a 
conformational change altering its three dimensional structure
135,136
. This shape change 
Figure 4: Formation of the DISC in Response to Fas Activation. After ligation of Fas (CD95) by FasL 
(CD95L) this allows for the recruitment of FADD via homotypic interactions between DD. FADD will then 




exposes the Fas cytoplasmic DD which subsequently allows for interactions with other 
DD containing proteins. The major scaffold protein responsible for the recruitment of 
effector molecules and stabilization of the DISC is the Fas-associated death domain 
(FADD)
130
. FADD is a cytosolic protein that possesses a DD near its C-terminal which is 
responsible for mediating its association with activated Fas. Near its N-terminal FADD 
possesses another protein-protein interaction domain capable of mediating homotypic 
interactions called a death effector domain (DED)
109
. FADD is responsible for the 




 Caspases comprise a family of cysteine proteases that are responsible for 
initiating and executing the apoptotic program. All caspases are initially translated in an 
enzymatically inactive, or pro-, form also known as a zymogen. In order for caspases to 
acquire enzymatic activity, they need to be catalytically processed. There are two generic 
categories of caspases: initiator and executioner caspases. Caspases-8, -9, and -10 are 
considered initiator caspases because these are the first caspases activated in response to 
various forms of pro-apoptotic stimuli. The initiator caspases are capable of auto-
catalytically processing themselves and as such can positively regulate their own activity. 
Caspases-3, -6, and -7 are the major executioner caspases. These caspases are substrates 
for the initiator caspases which are responsible for processing them from their inactive 
form to their enzymatically active form. Once active, they recognize and cleave their 
corresponding substrates which cause the morphological changes observed in cells 
undergoing apoptosis.  
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 Caspases-8 and -10 are the initiator caspases activated in response to Fas 
activation
137,138
. Procaspase-8 exists in two major isoforms, procaspase-8a and -8b, with 
both isoforms present in the DISC
139,140
. Procaspase-8 has limited substrate specificity 
and only enzymatically processes itself or c-FLIP
141
. Currently, the favored model for 
caspase-8 activation is the induced proximity model of initiator caspase activation
142
. The 
current evidence suggests that when procaspase-8 is recruited to FADD in response to 
Fas activation this allows for an accumulation of enzyme in relative close 
proximity
132,137
. FADD acts as a scaffold which allows for procaspase-8 molecules to 
form dimers. These procaspase-8 dimers are capable of catalytically modifying and 
activating other procaspase-8 dimers
142–144
. Conversion of procaspase-8 to caspase-8 




 The conversion of procaspase-8 to the more enzymatically active caspase-8 
occurs rapidly after receptor activation. Using co-immunoprecipitation and subsequent 
immunoblotting experiments, the active form of caspase-8 was detected at the DISC 30 
seconds after receptor activation
140
. A steady increase in caspase-8 was detected at the 
DISC through 10 minutes with a drastic decrease in enzyme presence 20 minutes after 
receptor activation. Interestingly, the cytosolic pool of caspase-8 was detectible after 10 
minutes and plateaued 20 minutes after receptor activation
140
. Once in the cytosol, active 
caspase-8 would be capable of activating executioner caspases leading to the fulfillment 





Chapter 2: Effects of GBM-derived Exosomes on T cell viability 
Introduction 
 Glioblastoma multiforme is the most common and aggressive primary brain tumor 
in adults. The average survival rate after diagnosis is only 15 months, despite an 
aggressive treatment regime consisting of surgical resection, chemo- and radio-therapy
6,9
. 
One of the confounding factors responsible for this dismal prognosis is the immune 
suppression that occurs both locally, in the tumor microenvironment, as well as 
systemically
41,145
. Typically, GBM patients are not immune suppressed prior to tumor 
development, and upon resection of the tumor some aspects of cellular immunity return 
to normal
39
. However, a generalized immune suppressive state is reinstated following 
tumor recurrence. Considering the location of the tumor, a vast majority of peripheral 
lymphocytes never come into direct contact with the tumor. Taken together, these 
observations highlight the role for a tumor specific soluble factor or factors responsible 
for these immune suppressive effects. While much research has gone into investigating 
possible mechanisms of immune suppression in GBM, a potential the role for tumor-
derived exosomes remains poorly characterized. 
 Exosomes are small membrane bound vesicles of endocytic origin that contain 
mRNA, soluble proteins and transmembrane proteins
70
. Exosomes are released by a 
variety of cell types including cancer cells and activated immune cells
78,79,95,97,98
. 
Depending on their origin, exosomes can mediate a diverse array of physiologic 
functions. Exosomes isolated from tumor cells have been implicated in facilitating tumor 
progression, angiogenesis and immune suppression
96,98,99
. Specifically, exosomes isolated 
from melanoma, colorectal and prostate cancer cell lines contain the pro-apoptotic 
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molecule FasL and are capable of inducing apoptosis in activated lymphocytes
99–101
. 
While it is known that GBM cells release exosomes that are capable of transferring a 
functional form of the oncogenic receptor EGFRvIII to other tumor cells
95,96
, the effect of 
GBM-derived exosomes on the immune system has not been satisfactorily described. 
 Utilizing co-culture systems and cell viability assays with Jurkat T cells GBM-
derived exosomes, we investigated whether the release of exosomes might be an immune 
suppressive mechanism employed by glioblastoma multiforme. Our data demonstrate that 
GBM-derived exosomes are capable of reducing T cell viability and therefore could be a 
contributing factor to the observed systemic immune suppression observed in brain tumor 
patients. These are novel findings in glioma biology.   
Methods 
Cell lines 
 The established glioblastoma cell lines, T98G, LN-229 and U-138MG, were 
purchased from American Type Culture Collection (ATCC). GBM cells were maintained 
in Essential Modified Eagle’s Medium (EMEM) (Lonza) and supplemented with a final 
concentration of 10% fetal bovine serum (FBS) (PAA Laboratories) and penicillin and 
streptomycin (Lonza). The A3 T cell line (ATCC), which is a Jurkat T cell clone that is 
hypersensitive to FasL-induced apoptosis, and maintained in RPMI-1640 (Lonza) 
supplemented with 10% FBS (PAA Laboratories), 2mM sodium pyruvate (Lonza) and 
penicillin and streptomycin (Lonza). All cells were cultured in a humidified incubator at 






 GBM cells were grown in 150cm
2
 flasks until approximately 80% confluent, the 
culture supernatant was then aspirated and the cells were washed with sterile 1x PBS. 
After the cells were washed, the exosome isolation medium was added to the cells. The 
isolation media consisted of phenol red free DMEM (Lonza) supplemented with 2mM L-
glutamine (Lonza) and penicillin and streptomycin (Lonza). After 30 hours the exosome 
collection medium was removed and the cells were maintained with normal culture 
medium. Exosome isolation was conducted by one of two methods: differential 
ultracentrifugation or centrifugal concentration.  
 For differential ultracentrifugation, the exosome collection medium was 
centrifuged at 500 x g for 10 minutes in order to remove dead cells. The supernatant was 
removed and centrifuged at 10,000 x g for 30 minutes in order to remove cellular debris 
and cell fragments. The resulting supernatant was ultracentrifuged at 100,000 x g for 90 
minutes in order to pellet the exosomes. The supernatant was discarded and the exosome 
pellet was resuspended in 100μL of pre-chilled sterile 1x PBS. All centrifugation steps 
were performed at 4°C.  
 For exosomes collected using centrifugal concentration, the exosome collection 
medium was centrifuged at 500 x g for 10 minutes in order to pellet dead cells. Then the 
supernatant was removed and centrifuged at 10,000 x g for 30 minutes to remove cell 
fragments and cellular debris. The resulting supernatant was then applied to a 100,000 
Dalton centrifugal filter (Millipore) and centrifuged at 3,220 x g for 20 minutes. All 
centrifugation steps were performed at 4°C using pre-chilled centrifuge tubes. Once the 
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sample was concentrated, sterile PBS was used to wash the filters. Final sample volume 
was around 300μL. 
Cell Viability Assay 
 In order to determine the effect of GBM-derived exosomes on T cell viability, the 
Jurkat T cells were seeded in a 96-well plate at a final concentration of 5,000 cells/well. 
The cells were allowed to acclimate for 24 hours and were then treated with GBM-
derived exosomes, 100ng/mL of rFasL (Enzo Life Sciences), or phosphate buffered 
saline (PBS). After 24 hours viability was assessed using the Cell TiterGlo viability assay 
(Promega) according to the manufacturer’s directions. 
Results 
 Jurkat T cells were co-cultured with exosomes isolated by differential 
ultracentrifugation for 24 hours, and following the incubation, a cell viability assay was 
performed. Exosomes isolated from T98G, U87, LN-229 (Figure 5a) and U-138 MG 
(Figure 5b) were all capable of significantly decreasing T cell viability when compared to 













































































































































 When Jurkat T cells were treated with the exosome-enriched fraction isolated 
using a 100kDa centrifugal filter from U-138 MG cells, the exosome fraction 
significantly decreased cell viability compared to the controls (Figure 5c). Importantly, 
when the Jurkat T cells were treated with the exosome-depleted centrifugal filter flow 
through, there was no change in cell viability compared to untreated control (Figure 5c). 
 
 
Figure 5: Jurkat T cells were plated in 96-well plates and 
treated with exosomes derived from (a) LN-229, T98G, 
U87 (b) U-138MG (c) concentrated U-138MG exosomes 
or soluble proteins. After 24 hours a Cell TiterGlo 
viability assay was performed. *; p≤0.05 compared to 






 In order to better appreciate the effects GBM-derived exosomes could exert on the 
immune system, exosomes were isolated from several established brain tumor cell lines. 
Co-culture of GBM-derived exosomes with Jurkat T cells was sufficient to significantly 
decrease T cell viability (Figure 5a, 5b). However, due to the technique used to isolate the 
exosomes, the possibility of a contaminating soluble protein mediating these effects could 
not be ruled out. This confound was addressed by using 100kDa centrifugal filters to 
concentrate our exosome sample. This method specifically allowed for the separation of 
large macromolecular complexes and smaller secreted factors present in the culture 
medium. A decrease in cell viability was observed in T cells treated with the exosome 
fraction and not the soluble protein fraction (Figure 5c). Taken together, these data 
suggest that GBM-derived exosomes, and not some other secreted molecule, are 
responsible for the observed decrease in T cell viability.  
 We have demonstrated that GBM-derived exosomes are capable of reducing T 
cell viability compared to the untreated control. Mechanistically, cell death pathways 
may have been activated by exosome associated proteins such as FasL, but the activation 
of cascades that result in cell cycle arrest, such as CTLA-4 or TGF-β signaling, could not 
be eliminated. In order to determine if extrinsic apoptosis is activated by GBM-derived 
exosomes, the presence of FasL in the exosome samples was investigated. 
Chapter 3: Characterization of GBM Cell Lines and Derived Exosomes 
Introduction 
 Depending on the cell of origin, exosomes are capable of facilitating a broad 
range of physiologic functions. Exosomes isolated from dendritic cells are capable of 
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activating T cells and stimulating antitumor immune response leading to tumor 
clearance
146,147
. However, exosomes isolated from tumor cells are capable of mediating 
pro-tumor effects. In vitro experiments suggest that the horizontal transfer of exosome 
components between tumor cells could be responsible for mediating tumor progression.  
 Exosomes isolated from glioblastoma cells possess the oncogenic receptor 
EGFRvIII and can transfer the functional receptor between tumor cells
95,96
. The 
successful transfer of this receptor is sufficient to increase proliferation of the recipient 
tumor cells
95,96
, as well as increase the expression of the anti-apoptotic protein BclXL
95
. 
Exosomes isolated from gastric cancer cells are capable of activating the MAP kinase and 
Akt pathways in other cancer cells. In this manner, bulk tumor cells could be capable of 
stimulating proliferation and cell survival pathways in adjacent tumor cells via exosome 
release. 
 Tumor-derived exosomes may play a role in angiogenesis. Colorectal cancer-
derived exosomes are enriched in mRNAs involved in the M phase of mitosis and are 
capable of increased endothelial cell proliferation
98
. Likewise, exosomes isolated from 
GBM cells are enriched in mRNA and proteins involved in the angiogenic process
96
. 
 A role for tumor-derived exosomes has also been implicated in immune 
suppression. Exosomes isolated from a variety of cancer types contain the pro-apoptotic 
molecule FasL and are capable of inducing apoptosis in activated T cells
99–101
. 
Antagonistic antibodies to either FasL or its receptor, Fas, are sufficient to rescue T cells 
from apoptosis. These data suggest that exosome release may be an important mechanism 




 Previous experiments demonstrated that GBM-derived exosomes are capable of 
decreasing T cell viability (Figure 5). These observations could be due to activation of 
pathways responsible for cell cycle arrest or, more likely, induction of extrinsic 
apoptosis. A major ligand of the death receptors responsible for induction of extrinsic 
apoptosis is FasL
112
. Using immunoblot techniques, we were able to demonstrate that 
FasL is expressed by established GBM cell lines; however, we but could not detect FasL 
in the exosome fraction.  
Methods 
Cell lines 
 The established glioblastoma cell lines, T98G, LN-229 and U-138MG, were 
purchased from American Type Culture Collection (ATCC). They were maintained in 
EMEM (Lonza) and supplemented with a final concentration of 10% FBS (PAA 
Laboratories) and penicillin and streptomycin (Lonza). The A3 T cell line is a Jurkat T 
cell clone that is hypersensitive to FasL induced apoptosis, was maintained in RPMI-
1640 (Lonza) supplemented with 10% FBS (PAA Laboratories), 2mM sodium pyruvate 
(Lonza) and penicillin and streptomycin (Lonza). All cells were cultured in a humidified 
incubator at 37°C with 5% CO2. 
Exosome Isolation 
GBM cells were grown in 150cm
2
 flasks until approximately 80% confluent, the 
culture supernatant was aspirated, and the cells were washed with sterile 1x PBS. After 
the cells were washed, the exosome isolation medium was added to the cells. The 
isolation media was phenol red free DMEM (Lonza) supplemented with 2mM L-
glutamine (Lonza) and penicillin and streptomycin (Lonza). After 30 hours, the exosome 
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collection medium was removed and the cells were maintained with normal culture 
medium. 
 Exosomes were collected using centrifugal concentration. The exosome collection 
medium was centrifuged at 500 x g for 10 minutes in order to pellet dead cells. The 
supernatant was removed and centrifuged at 10,000 x g for 30 minutes to remove cell 
fragments and cellular debris. The resulting supernatant was then applied to a 100,000 
Dalton centrifugal filter (Millipore) and centrifuged at 3,220 x g for 20 minutes. All 
centrifugation steps were performed at 4°C using pre-chilled centrifuge tubes. Once the 
sample was concentrated sterile PBS was used to wash the filters. The final sample 
volume was 300μL. 
Reverse Transcriptase PCR 
 Total RNA was isolated from established GBM cell lines using IBI Total RNA 
mini kit following the manufacturer’s instructions. Total RNA was then converted into 
cDNA using the Reverse Transcription System (Promega). Amplification of FasL or actin 














The resulting PCR product was separated on a 1% agarose gel in 1x Tris Acetate EDTA 
buffer. 
Western blot 
 Whole cell lysates were prepared by growing cells in culture conditions until they 
were 80% confluent. The culture medium was then aspirated and the cells were washed 
with an excess of 1x PBS. The cells were lysed using 1x SDS lysis buffer (20mM HEPES 
and 1% SDS) and genomic DNA was sheared using a syringe and a 12 gauge needle. 
Protein concentrations of the lysates were determined using the BCA assay (Thermo 
Scientific). Samples were resolved on pre-cast SDS-PAGE gels (BioRad) and transferred 
to nitrocellulose. 
 The nitrocellulose membranes were blocked for 30 minutes in a 5% non-fat milk 
solution in Tris buffered saline with Tween 20 (20mM Tris, 150mM NaCl, 0.1% Tween). 
After the membranes had been blocked, the nitrocellulose membranes were probed with 
primary antibodies, either anti-FasL or anti-CD9 (Abcam), for 1 hour. Then the 
nitrocellulose membranes were probed with HRP-conjugated anti-mouse secondary 
antibody for an hour. Bands were visualized using SuperSignal West Pico 
Chemiluminescent substrate (Thermo Scientific).  
Results 
 As determined by RT-PCR, all three GBM cell lines investigated (T98G, U-
138MG, LN-229) express the FasL transcript (Figure 6). To further verify the expression 
of FasL, Western blot analysis was used. As shown in Figure 7, all three cell lines 
expressed the FasL protein. However, neither FasL nor the exosomal marker CD9 was 






















 FasL expression by established GBM cell lines was determined at the mRNA 
level as well as at the protein level (Figures 6 and 7). The bands corresponding to the 
amplified FasL transcript (500bp) in all three cell lines were detected after gel 
electrophoresis (Figure 6). In order to be confident that the cell lines expressed FasL, 
FasL Actin 
U138 
FasL Actin FasL Actin 
LN229 T98 
Figure 6: Total RNA was isolated from the indicated cell lines and was reverse transcribed to 
cDNA using random oligomers. The transcripts for FasL or Actin were specifically amplified using 
polymerase chain reaction and subsequently run on a 1% agarose gel using Tris Acetate EDTA 
running buffer. 
Figure 7: Whole cell lysates or exosome lysates were separated on a 4-15% polyacrylamide gel. 
Proteins were transferred to nitrocellulose membrane and probed for the exosomal marker CD9 or 
FasL. FasL is 35kDa and CD9 is 20kDa. 
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Western blot was used to determine the presence of the protein. Consistent with the 
results from the RT-PCR experiments, FasL was detected in all cell lines investigated 
(Figure 7). However, the expression of FasL by the parent cells does not guarantee the 
presence of FasL in GBM-derived exosomes. Exosomes were isolated using a 100kDa 
centrifugal filter and subjected to Western blot for FasL and the exosomal marker CD9. 
Neither FasL nor CD9 was detected in the exosome fraction, despite both being found in 
the parent cell lines (Figure 7). These results do not rule out the presence of FasL in the 
exosome fraction. Because the exosomal marker CD9 was not detected, this could 
indicate that the protein concentration of the exosome fraction was below the detection 
limit for Western blots. Therefore, considering a signal for the exosomal marker CD9 
was not detected, the lack of a FasL signal may only indicate that there was not a 
sufficient amount of the protein in the exosome fraction to produce a signal.     
Chapter 4: Induction of Caspase Cascade by GBM-derived Exosomes 
Introduction 
 A role for exosome mediated immune suppression has been implicated in a 
variety of tumor types including melanoma, colorectal and prostate cancer. These cancer 
types express the pro-apoptotic molecule FasL which binds to its receptor, Fas, and 
activates the extrinsic cell death pathway. Exosomes isolated from these cell types also 
contain FasL and are capable of inducing FasL-dependent apoptosis in activated T 
cells
99–101
. Studies show that established GBM cell lines, as well as freshly resected 
clinical samples, express FasL.  
A recent study highlighted the importance of FasL expression in GBM in 
mediating immune suppression. Rat glioma cell lines (which normally express FasL) 
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were engineered to no longer express the protein and in vitro apoptosis assays indicated 
the FasL knockout cell lines induced significantly less T cell death compared to the wild 
type cell line
68
. Additionally, rats that were injected with the FasL knockout cells had a 
longer overall survival compared to rats who received the wild type cells
68
. When the 
tumors from the treated and control rats were examined for the presence of tumor 
infiltrating lymphocytes there were more lymphocytes, in the FasL knockout tumors than 
the wild type tumors
68
. The increased survival time of the FasL knockout tumors can be 
attributed to the elevated presence of lymphocytes in the tumor bed. This would indicate 
that FasL expression is a major component of the immune suppressive repertoire utilized 
by GBM to escape recognition and subsequent clearance by the immune system.  
 The ability of GBM to mediate immune suppression through the induction of 
lymphocyte apoptosis appears to be an important mechanism in immune suppression. 
However, a role for GBM-derived exosomes in immune suppression has not been 
investigated. In order to determine if GBM-derived exosomes are capable of activating 
the extrinsic apoptotic pathway, the activity of downstream effector molecules was 
investigated. In response to death receptor activation, a series of enzymatic reactions 
occur resulting in the activation of a class of proteins called caspases. Directly 
downstream of the death receptor is caspase-8. In response to death receptor activation 
caspase-8 is activated which activates caspase-3
112,140
. This caspase cascade results in 
apoptotic program and cell death. In order to determine the ability of GBM-derived 







 The established glioblastoma cell lines, T98G, LN-229 and U-138MG, were 
purchased from ATCC. They were maintained in EMEM (Lonza) and supplemented with 
a final concentration of 10% FBS (PAA Laboratories) and penicillin and streptomycin 
(Lonza). The A3 T cell line is a Jurkat T cell clone that is hypersensitive to FasL induced 
apoptosis was maintained in RPMI-1640 (Lonza) supplemented with 10% FBS (PAA 
Laboratories), 2mM sodium pyruvate (Lonza) and penicillin and streptomycin (Lonza). 
All cells were cultured in a humidified incubator at 37°C with 5% CO2. 
Exosome Isolation 
GBM cells were grown in 150cm
2
 flasks until approximately 80% confluent, the 
culture supernatant was aspirated and the cells were washed with sterile 1x PBS. After 
the cells were washed the exosome isolation medium was added to the cells. The 
isolation media was phenol red free DMEM (Lonza) supplemented with 2mM L-
glutamine (Lonza) and penicillin and streptomycin (Lonza). After 30 hours the exosome 
collection medium was removed and the cells were maintained with normal culture 
medium. 
 Exosomes were collected using centrifugal concentration. The exosome collection 
medium was centrifuged at 500 x g for 10 minutes in order to pellet dead cells. Then the 
supernatant was removed and centrifuged at 10,000 x g for 30 minutes to remove cell 
fragments and cellular debris. The resulting supernatant was then applied to a 100,000 
Dalton centrifugal filter (Millipore) and centrifuged at 3,220 x g for 20 minutes. All 
centrifugation steps were performed at 4°C using pre-chilled centrifuge tubes. Once the 
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sample was concentrated sterile PBS was used to wash the filters. Final sample volume 
was around 300μL. 
Caspase Activity Assay 
Jurkat T cells were seeded in a 96-well plate at a final concentration of 5,000 
cells/well. The cells were allowed to acclimate for 24 hours and were treated with GBM-
derived exosomes, 100ng/mL of rFasL (Enzo Life Sciences) or phosphate buffered saline 
(PBS). Activation of a caspase cascade in response to exosome or rFasL treatment was 
determined using Caspase-8 Glo or Caspase-3/7 Glo (Promega), per the manufacturer’s 
instructions. Neutralizing assays were conducted using the Fas antagonist monoclonal 
antibody ZB4 (Millipore). Jurkat T cells were pretreated with 500ng/mL of ZB4 for 1 
hour before the addition of either GBM-derived exosomes or rFasL. 
Results 
 Jurkat T cells were treated with increasing concentrations of rFasL to determine 
sensitivity to FasL-mediated caspase-8 activation. rFasL was able to increase caspase-8 
activity in Jurkat T cells at all concentrations and time points (Figure 8). Pre-treatment of 
Jurkat T cells with the Fas neutralizing antibody, ZB4, prior to addition of rFasL blocked 
caspase activation (Figure 9). Treatment with the antibody alone did not effect T cell 











































































































































Figure 8: Jurkat T cells were plated in 96-well plates at a concentration of 50,000 cells/mL and were treated 
with either 10ng/mL, 50ng/mL or 100ng/mL of rFasL. Caspase-8 activity in response to rFasL treatment was 
assayed (a) 4 hours (b) 8 hours (c) 20 hours or (d) 24 hours post-treatment using Caspase-8Glo. *; p≤0.05 









































































Figure 9: Jurkat T cells were plated in a 96-well plate at a concentration of 50,000 cells/mL and were treated 
with the Fas neutralizing antibody, ZB4. Jurkat T cells were treated with the indicated concentration of ZB4 
alone in combination with 100ng/mL of rFasL. After 24 hours a Cell TiterGlo viability assay was performed. *; 
p≤0.05 compared to UT. Error bars ±S.E. 
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 Co-culturing Jurkat T cells with GBM-derived exosomes caused a significant 
increase in caspase-8 activity (Figure 10). Exosomes derived from T98G cells activated 
caspasae-8 significantly more than LN-229- or U-138MG-derived exosomes. T98G-




































































Figure 10: Jurkat T cells were plated in 96-well plates at a concentration of 50,000 cells/mL and 
were treated with exosomes derived from T98G, LN-229, U-138MG or with rFasL. After 24 


























Figure 11: Jurkat T cells were plated in 96-well plates at a concentration of 50,000 cells/mL and treated 
with T98G-derived exosomes. After 4 hours caspase-3 activity was determined using Caspase-3/7Glo. *; 
p≤0.05 compared to UT. Error bars ±S.E. 
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 Pre-treatment of Jurkat T cells with ZB4 prior to co-culture with GBM-derived 
exosomes produced variable results. Exosomes isolated from all three GBM cell lines 
were capable of increasing caspase-8 activity. However, the combination of ZB4 and U-
138MG- and LN-229-derived exosomes significantly increased caspase-8 activation 
compared to exosome treatment alone (Figure 12). There was no difference in caspase-8  
activity in the presence or absence of ZB4 when Jurkat T cells treated with T98G-derived 












 Jurkat T cells treated with ZB4 and exosomes had significantly decreased cell 
viability compared to cells treated with exosomes alone (Figure 13). Consistent with the 
observed changes in caspase-8 activity these differences were only observed in Jurkat T 
cells treated with U-138MG- and LN-229-derived exosomes. There was no difference in 
viability in T cells treated with T98G-derived exosomes (Figure 13). 
Figure 12: Jurkat T cells were plated in 96-well plates at a concentration of 5,000 cells/well. Groups labeled 
mAb were pretreated with a Fas neutralizing antibody before being co-cultured with GBM-derived exosomes. 
After 24 hours caspase-8 activity was determined using Caspase-8Glo. * indicates significance (p≤0.05) with 


































































































 The ability of GBM-derived exosomes to induce T cell apoptosis via a FasL-
dependent mechanism was investigated in response to reports of exosomes from other 
cancer types being able to mediate these effects. First, the sensitivity of Jurkat T cells to 
FasL-mediated apoptosis was assessed. Jurkat T cells were treated with increasing 
concentrations of rFasL and caspase-8 activity was determined at 4, 8, 20 or 24 hours 
post-treatment. Caspase-8 is immediately downstream of Fas activation, therefore 
assaying its activity is a good indicator for the signaling status of the receptor. Caspase-8 
activity increased in response to all concentrations of rFasL used (Figure 8). A dose-
dependent increase of caspasase-8 activity was observed at 4 and 8 hours post-treatment 
(Figure 8a, 8b). Increased concentrations of rFasL should result in greater receptor 













































































Figure 13: Jurkat T cells were plated in 96-well plates. Groups labeled mAb were pre-treated 
with ZB4 before being co-cultured with GBM-derived exosomes. After 24 hours a Cell TiterGlo 
viability assay was performed. *; indicates significance (p≤0.05) with untreated. ǂ; indicates 
significance between treatments. Error bars ±S.E. 
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hours post-treatment caspase-8 activity remained elevated but had reached a steady state 
(Figure 8c, 8d).  
 In order to determine the specificity of these effects to the Fas/FasL pathway the 
Fas neutralizing antibody, ZB4, was used. Jurkat T cells were pre-treated with increasing 
concentrations of neutralizing antibody for one hour before treatment with rFasL. Pre-
treatment of cells with the Fas neutralizing antibody was capable of rescuing T cell 
viability at all concentrations used (Figure 9). Treatment of Jurkat T cells with only Fas 
neutralizing antibody had no effect on viability at any of the concentrations used (Figure 
9). Taken together, these data indicate that treatment of Jurkat T cells with rFasL is 
sufficient for the induction of caspase-8 activity and capable of reducing T cell viability.  
 These experiments were replicated using GBM-derived exosomes. Caspase-8 
activity increased in Jurkat T cells that were treated with exosomes isolated from LN-
229, U-138MG or T98G (Figure 10). However, T98G-derived exosomes had the greatest 
effect on enzyme activity. Therefore, T98G-derived exosomes were used to determine if 
GBM-derived exosomes could activate a caspase cascade indicative of FasL signaling. 
Not only were T98G-derived exosomes capable of inducing caspase-8 activity, but this 
resulted in a significant increase of caspase-3 activity as well (Figure 11). These data 
indicate that GBM-derived exosomes are capable of activating a caspase cascade 
indicative of FasL signaling. 
 Next, T cells were treated with ZB4 before the addition of GBM-derived 
exosomes. Jurkat T cells that were treated with both the Fas neutralizing antibody and 
exosomes isolated from LN-229 or U-138MG had significantly more caspase-8 activity 
than Jurkat T cells treated with just GBM-derived exosomes (Figure 12). There was no 
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difference in caspase-8 activity in T cells that were treated with T98G-derived exosomes 
in the presence or absence of ZB4 (Figure 12). Consistent with these observations Jurkat 
T cells that were treated with LN-229- or U-138MG-derived exosomes and ZB4 had 
decreased cell viability compared to Jurkat T cells that were only treated with GBM-
derived exosomes (Figure 13). There was no difference in cell viability with T cells 
treated with T98G-derived exosomes (Figure 13).  
 Given the contradictory nature of the neutralizing antibody data it is feasible that 
the antibody facilitates Fas receptor cross-linking and subsequent receptor activation. 
This would lead to increased caspase-8 signaling and results in decreased T cell viability. 
However, given results of previous experiments, it is clear that ZB4 is capable of 
neutralizing the apoptotic effect of rFasL (Figure 9), and treatment of Jurkat T cells with 
ZB4 alone does not have an effect on T cell viability (Figure 9). The effects observed 
from combined treatment of Jurkat T cells with GBM-derived exosomes and ZB4 are 
specific to that treatment condition.  
One possible explanation for these contradictory results could be that GBM-
derived exosomes could contain an immunoglobulin receptor. When the Jurkat T cells 
were pre-treated with the Fas neutralizing antibody, this allowed for specific interactions 
between the antigen binding domain of the antibody to bind to its epitope on the Fas 
receptor. This would leave the Fc region of the antibody exposed. In the presence of an 
exosomal associated immunoglobulin receptor, the Fc regions of multiple antibodies 
could be bound. This could potentially lead to cross-linking of Fas receptor subunits and 
induce signaling in the absence of ligand binding. This possible mode of action is 
currently being investigated.  
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Chapter 5: Conclusions 
  Glioblastoma multiforme is a devastating disease with an average survival rate of 
15 months after diagnosis
6
. Novel treatment strategies are desperately needed in the fight 
against brain tumors. Recent efforts have investigated the effectiveness of immune based 
therapies in the treatment of malignant gliomas
148
. Pre-clinical studies as well as phase 
I/II clinical trials have reported putative successes using immunotherapies targeting 
GBM
11,20–22,24,25,148
. However, to date, there are no FDA approved immunotherapies for 
the treatment of GBM. A potential confounding factor to the application of 
immunotherapies in GBM could be the degree of systemic immune suppression afforded 
by the tumor. If a patient’s immune system is predisposed to be suppressed or 
hyporesponsive due to tumor specific factors, therapeutic intervention might not be 
sufficient to elicit a robust antitumor immune response. The diverse repertoire of 
immunosuppressive factors employed by GBM needs to be antagonized in order to 
increase the efficacy of immunotherapies. The most successful immunotherapeutic 
regime will simultaneously target the tumor itself as well as factors produced by the 
tumor responsible for immune suppression.   
 The immune system of GBM patients is severely compromised. Peripheral blood 
lymphocytes from GBM patients are hyporesponsive, and there is an overall decrease in 
the number of circulating lymphocytes
145
. These deficiencies are restored after tumor 
resection but quickly return with tumor recurrence
39
. This indicates that the factors 
responsible for immune suppression are tumor specific and since most peripheral 
lymphocytes never come into direct contact with the tumor the factors mediating immune 
suppression must be soluble. These molecules have the ability to diffuse away from the 
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tumor bed, enter into circulation and exert their immunomodulatory effects on distant 
populations of immune cells. GBM-derived exosomes are an attractive candidate that 
fulfills both of these proposed criteria for immune suppression. Considerable research has 
gone into investigating immunosuppressive mechanisms employed by GBM 
41,145
 but the 
role of GBM-derived exosomes has not been investigated to date. 
 Exosomes are small vesicles (50-100nm of endocytic origins that contain mRNA, 
miRNA and proteins. Exosomes are released by a variety of cell types, including tumor 





 and tumor progression
95
. A role for exosomes in immune 
suppression for colorectal, prostate cancer and melanoma has been proposed. FasL is 
present in exosomes isolated from those cancer types and will activate extrinsic apoptosis 
when co-cultured with T cells
99–101
. Clinical samples, as well as established GBM cell 
lines, express FasL
68
 but the presence of FasL in GBM-derived exosomes and its 
functional significance has never been investigated. We have shown that GBM-derived 
exosomes are capable of inducing apoptosis in Jurkat T cells. This is a novel finding in 
glioma biology. 
 In the present study we have shown that the established GBM cell lines LN-229, 
U-138MG and T98G all express the pro-apoptotic molecule FasL. This was shown by 
reverse transcriptase PCR and subsequent agarose electrophoresis (Figure 6) and 
confirmed with immunoblotting techniques (Figure 7). Expression of FasL by the parent 
cells does not necessarily mean that it will be present in the exosomes. Western blot 
analysis of GBM-derived exosomes was unable to detect either FasL or the exosomal 
marker CD9. The inability to detecte CD9 in our sample indicates that the protein 
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concentration was most likely below the detection level for Western blot analysis. The 
presence or absence of FasL in our samples cannot be determined from our data. 
 Functional assays were performed to determine the effect of GBM-derived 
exosomes on Jurkat T cells. The co-culture of Jurkat T cells with exosomes isolated from 
LN-229, T98G, U87 and U-138MG cell lines was sufficient to decrease T cell viability 
when compared to the untreated control (Figure 5a, b). However, membrane bound FasL 
can be enzymatically cleaved into a soluble isoform
149
 which has been reported to be 
found in cyst fluid isolated from malignant gliomas
150
. In order to determine whether 
exosomes or a contaminating soluble protein were responsible for the decreased T cell 
viability, exosomes were isolated using 100kDa centrifugal filters. Components of the 
cell culture medium smaller than 100kDa should pass through the filter while 
components larger than 100kDa are retained. Only the exosome-enriched fraction was 
capable of decreasing T cell viability (Figure 5c). When Jurkat T cells were treated with 
the fraction containing secreted components <100kDa, there was no difference in T cell 
viability when compared to the untreated control (Figure 5c). 
 Taken together, these data indicate that all three GBM cell lines express FasL and 
exosomes isolated from those cell lines, not a secreted protein, are capable of decreasing 
T cell viability in co-culture assays. However, the molecular cargo of GBM-derived 
exosomes is relatively unknown. The exosomes could be activating cell cycle arrest 
pathways in T cell like TGF-β or CTLA-4 signaling. In order to determine if GBM-
derived exosomes are capable of activating the FasL/Fas signaling pathway, the activity 
of downstream signaling molecules of Fas activation were investigated. 
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 Shortly after FasL binds to Fas the inactive procaspase-8 is converted into the 
active form of the enzyme, caspase-8
140
. Therefore, assaying for caspase-8 activity is a 
good indicator of the signaling status of Fas. Caspase-8 activity is increased in Jurkat T 
cells that were co-cultured with GBM-derived exosomes (Figure 10). Specifically, T98G-
derived exosomes had the greatest increase caspase-8 activity. After caspase-8 is 
activated in response to Fas signaling it in turn cleaves the inactive procaspase-3 which 
converts it into active caspase-3. Caspase-3 is referred to as an executioner caspase and is 
responsible for the fulfillment of the apoptotic program. Caspase-3 activity is increased in 
T cells co-cultured with T98G-derived exosomes (Figure 11). These data indicate that 
GBM-derived exosomes are sufficient to stimulate a caspase cascade indicative of FasL-
induced apoptosis in T cells. In order to show that this signaling cascade was activated by 
FasL a series of experiments utilizing a Fas neutralizing antibody were performed. 
 Contradictorily, caspase-8 activity was increased in Jurkat T cells that had been 
treated with both ZB4 and exosomes derived from LN-229 or U-138MG when compared 
to T cells that had been only treated with LN-229- or U-138MG-derived exosomes 
(Figure 12). There was no significant difference in caspase-8 activity in Jurkat T cells 
treated with T98G-derived exosomes in the presence or absence of ZB4 (Figure 12). 
Caspase-8 activity inversely correlated with T cell viability in response to exosome 
treatment. Jurkat T cells that had been treated with both ZB4 and exosomes from LN-229 
or U-138MG had reduced viability as compared to T cells treated with exosomes alone 
(Figure 13). There was no statistical difference in T cell viability when co-cultured with 
T98G-derived exosomes in the presence or absence of ZB4 (Figure 13).  
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 To summarize, when Jurkat T cells are pre-treated with the Fas neutralizing 
antibody ZB4 then subsequently co-cultured with exosomes derived from LN-299 or U-
138MG, they experienced more caspase-8 activity than in T cells treated with exosomes 
alone. The combination treatment also significantly decreases T cell viability when 
compared to T cells that were treated with only exosomes. However, there is no 
significant difference in caspase-8 activity or T cell viability in the presence or absence of 
ZB4 when T cells are treated with T98G-derived exosomes.  
 The Fas neutralizing is capable of blocking rFasL-induced apoptosis (Figure 9) 
and treatment of Jurkat T cells with ZB4 alone does not have an effect of T cell viability 
(Figure 9). Therefore, something about treating the Jurkat T cells with ZB4 and the 
exosomes is responsible for these contradictory results. One possibility is that following 
pre-treatment with ZB4 the antigen binding domain of the antibody binds to its epitope 
on Fas. This would normally be sufficient to disrupt the interactions between Fas and 
FasL which would inhibit the ability of Fas to induce apoptosis. However, if the GBM-
derived exosomes contain an immunoglobulin receptor it is possible that they bind to the 
Fc regions of multiple ZB4 bound Fas receptors. This could lead to receptor cross-linking 
and subsequent activation. This would explain the significant increase in caspase-8 
activity in T cells treated with both ZB4 and LN-229- or U-138MG-derived exosomes. It 
is possible that T98G cells do not express the immunoglobulin receptor or it could be 
absent from T98G-derived exosomes. This would explain the lack of change in either 
caspase-8 activity or T cell viability upon co-culture with T98G-derived exosomes in the 
presence or absence of ZB4.  
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 This hypothesis could be tested by performing a papain digestion on the ZB4 
antibody. Papain is a protease that is able to cleave the Fc region from IgG molecules. 
This would separate the Fc region from the antigen binding domains of the antibody. The 
ability of  an immunoglobulin receptor to crosslinking antibody bound Fas is dependent 
on the Fc region.  Therefore, if these experiments were repeated using only the antigen 
binding domain of ZB4 as the neutralizing agent it could be determined if the apoptotic 
effects of GBM-derived exosomes were augmented via this indirect mechanism.  
 Regardless of mechanism our data strongly indicates that GBM-derived exosomes 
are capable of inducing apoptosis in Jurkat T cells. Co-culturing Jurkat T cells with 
GBM-derived exosomes is sufficient for induction of apoptosis. This is a novel finding in 
glioma biology and indicates a role for exosome release in immune suppression. The 
development of therapies aimed at antagonizing the biogenesis and secretion of exosomes 
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